Shares of Amdocs Limited (NASDAQ:DOX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $101.20.
Separately, StockNews.com cut Amdocs from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 28th.
View Our Latest Research Report on DOX
Institutional Trading of Amdocs
Several institutional investors and hedge funds have recently bought and sold shares of DOX. Private Trust Co. NA raised its position in shares of Amdocs by 62.9% during the 3rd quarter. Private Trust Co. NA now owns 303 shares of the technology company's stock valued at $27,000 after acquiring an additional 117 shares in the last quarter. Brooklyn Investment Group bought a new stake in Amdocs during the third quarter valued at $28,000. Jones Financial Companies Lllp acquired a new stake in shares of Amdocs during the fourth quarter worth $36,000. SBI Securities Co. Ltd. bought a new position in shares of Amdocs in the 4th quarter worth about $41,000. Finally, Global Retirement Partners LLC boosted its holdings in shares of Amdocs by 45.6% in the 4th quarter. Global Retirement Partners LLC now owns 559 shares of the technology company's stock valued at $48,000 after buying an additional 175 shares during the period. Institutional investors and hedge funds own 92.02% of the company's stock.
Amdocs Stock Down 1.2 %
Amdocs stock traded down $1.07 during midday trading on Wednesday, hitting $90.95. 561,422 shares of the company were exchanged, compared to its average volume of 685,291. The company has a market cap of $10.27 billion, a PE ratio of 21.10, a price-to-earnings-growth ratio of 1.47 and a beta of 0.68. Amdocs has a fifty-two week low of $74.41 and a fifty-two week high of $93.34. The company's fifty day moving average price is $87.89 and its 200-day moving average price is $87.34. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.16 and a quick ratio of 1.20.
Amdocs (NASDAQ:DOX - Get Free Report) last announced its earnings results on Tuesday, February 4th. The technology company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.19). Amdocs had a net margin of 10.19% and a return on equity of 18.89%. On average, research analysts predict that Amdocs will post 6.21 EPS for the current fiscal year.
Amdocs Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Monday, March 31st will be given a dividend of $0.527 per share. This is a boost from Amdocs's previous quarterly dividend of $0.48. The ex-dividend date is Monday, March 31st. This represents a $2.11 annualized dividend and a dividend yield of 2.32%. Amdocs's dividend payout ratio (DPR) is presently 48.72%.
Amdocs Company Profile
(
Get Free ReportAmdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
Recommended Stories

Before you consider Amdocs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amdocs wasn't on the list.
While Amdocs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.